Results 81 to 90 of about 5,039,222 (352)
Foot-print of Claudin and Occludin Transcriptome in Colorectal Cancer [PDF]
arXiv, 2020 Background and Purpose: Colorectal cancer as a leading cause of mortality worldwide, can be regarded as a relatively common and fatal disease with increasing incidence over recent years. Colorectal cancer is characterized by uncontrolled growth of abnormal cells occurring in different parts of the colon.
arxiv
A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini +11 more
wiley +1 more source
An Artificial Intelligence Outlook for Colorectal Cancer Screening [PDF]
arXiv, 2022 Colorectal cancer is the third most common tumor in men and the second in women, accounting for 10% of all tumors worldwide. It ranks second in cancer-related deaths with 9.4%, following lung cancer. The decrease in mortality rate documented over the last 20 years has shown signs of slowing down since 2017, necessitating concentrated actions on ...
arxiv
Ca, 2020 Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population‐based cancer occurrence.
R. Siegel, K. D. Miller, A. Jemal
semanticscholar +1 more source
Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Molecular Oncology, EarlyView.Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi +6 more
wiley +1 more source
BMC Cancer, 2019 Background Neoadjuvant chemoradiotherapy is regarded as the standard of treatment for locally advanced lower rectal cancer, although some of these cases are systemic, and distant control may be inadequate.
Takuya Shiraishi +5 more
doaj +1 more source
BMC Cancer, 2019 Background Patients suffering from high risk stage II colon cancer (CC) may benefit from adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification.
Ann C. Eriksen +6 more
doaj +1 more source
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
New England Journal of Medicine, 2009 BACKGROUND We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and ...
E. Van Cutsem +17 more
semanticscholar +1 more source
Nature Reviews Clinical Oncology, 2020 An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal–Anal Task Forces of the United States ...
A. Dasari +42 more
semanticscholar +1 more source
BMJ, 2013 This is the final version of the article. Available from the publisher via the DOI in this record. ; This is one of a series of occasional articles highlighting conditions that may be more common than many doctors realise or may be missed at first presentation.
Hamilton, W, Coleman, MG, Rubin, G
openaire +4 more sources